Evaluating Confounding Control in Estimations of Influenza Antiviral Effectiveness in Electronic Health Plan Data

    Basic Details
    Date
    Wednesday, February 2, 2022
    Type
    Publication
    Description

    Observational studies of oseltamivir and influenza complications could suffer from residual confounding. Using negative control risk periods and a negative control outcome, we examined confounding control in a claims-based study of oseltamivir and influenza complications (pneumonia, all-cause hospitalization, antibiotic dispensing). Within the FDA's Sentinel System we identified individuals ≥18 years initiating oseltamivir on the influenza diagnosis date versus those who did not, during three influenza seasons (2014-2017). We evaluated primary outcomes in the following 1-30 days (primary risk period) and 61-90 days (negative control period), and non-vertebral fractures (negative control outcome) in days 1-30. We estimated propensity score-matched risk ratios (RR) per season.

    Author(s)

    Phyo T. Htoo, Gregory Measer, Robert Orr, Justin Bohn, Alfred Sorbello, Henry Francis, Sarah K. Dutcher, Austin Cosgrove, Amanda Carruth, Sengwee Toh, Noelle M. Cocoros

    Corresponding Author

    Noelle M. Cocoros; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute

    Email: noelle_cocoros@harvardpilgrim.org